When Sterility Can’t Be Proven
In 2026, a single manufacturer’s documentation failure became a nationwide hospital supply-chain problem. Huons Co. Ltd. recalled every lot of its lidocaine and bupivacaine injection, and the ripple pulled product from BD, Teleflex, and Medline with it.
ALL
LOTS
Recalled — no exceptions
210,625
Ampules, Spectra alone
BD
Teleflex · Medline downstream vendors hit
ZERO
Confirmed contamination
What Happened
An FDA inspection of Huons’ manufacturing facility in November 2025 found significant CGMP violations. The result was a voluntary recall of all lots of lidocaine HCl and bupivacaine-in-dextrose injection beginning in April 2026, followed in May by expansion to additional repackagers and distributors, and then an FDA warning letter in June 2026.The Root Cause
It wasn’t contamination. It was proof.
Huons could not demonstrate — through its manufacturing and quality records — that its products met sterility standards. When a manufacturer can’t document sterility assurance, regulators treat the product as unsterile. Every lot has to come back, contamination or not.How One Failure Cascaded
Huons
Manufacturer (sterility unproven)
Spectra + Repackagers
Repackaging and distribution layer
BD · Teleflex · Medline
Kits and downstream vendor exposure
Hospitals
Health systems and supply-chain disruption
Why It Matters
Lidocaine and bupivacaine are used throughout the hospital — from the ED to the OR. Recalling all lots at once made this one of 2026’s most disruptive supply-chain recalls. And it was preventable: the failure was in the paperwork, not the product. Rigorous, provable sterility-process documentation would have kept these injectables on the shelf.How RecallWire Helps
RecallWire helps hospitals detect recalls the moment they hit, trace every affected lot across vendors, and document the response end to end — so your team knows before impacted product reaches the shelf.